Selskabets formål er at eje aktier, anparter og andre investeringsinstrumenter.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 31.4 mio. | 27 t. | 780 t. | 52 t. | 1 | |
CVR: 42844918
Secondary names: Bio Assets ApS
Compared to 20.872 companies in Anden finansiel formidling i.a.n.
Comparison is based on industry median values
EY Godkendt Revisionspartnerselskab appointed as auditor
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB resigned as auditor
Companies in the same industry and area
CVR 41951885
CVR 38221361
CVR 26161029
CVR 46224507
CVR 31581818
The financial health of Maigaard & Molbech II ApS shows signs of recovery, with revenue increasing significantly from 9,085,264 DKK in 2022 to 31,400,000 DKK in 2024. However, profitability remains a concern, as evidenced by a marginal profit of only 27,000 DKK in 2024, following a loss of 36,000 DKK in 2023. The company's equity has fluctuated, rising to 52,000 DKK in 2024 from 25,000 DKK in 2023, indicating some stability but still low overall. Operating within the alternative financial intermediation sector, Maigaard & Molbech II ApS is positioned for growth, yet must address its thin profit margins and overall equity to strengthen its market position.
AI-generated summary
companydata.dk